Yesterday, eMagin Corporation announced that it has commenced a 2-year, $6 million program to develop an ultra-high resolution OLED microdisplay. Managed by the Telemedicine and Advanced Technology Research Center of the US Army Medical Research and Materiel Command, the program introduces the third phase of a multiple year effort to provide a prototype of an ultra-high resolution display system suitable for several applications within Army medicine and military simulation and training.

The Widescreen Ultra eXtended Graphics Array (WUXGA) microdisplay will be sized for a less than one-inch diagonal with over 7 million pixels at a 9.6 micron color pixel pitch. The program involves optic design for a wide field-of-view between 60 and 80 degrees.

Currently, eMagin’s OLED microdisplays already meet military specifications across diverse applications, including IR night vision and tactical situational awareness HMDs, in addition to being integrated into commercial devices such as thermal video cameras and video gaming systems.

Susan

DrStockPick.com Stock Report!

Tuesday September 15, 2009

**************************************************************

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained favorable results from recently completed Phase 1 studies of LX4211 and announced today that it has initiated a Phase 2 clinical trial of the drug candidate in patients with type 2 diabetes mellitus. LX4211 is an orally-delivered, small molecule drug candidate that inhibits the sodium glucose transporter 2 (SGLT2). LX4211 is Lexicon’s fourth drug candidate currently being tested in Phase 2 clinical trials.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Medtronic, Inc. (NYSE: MDT),